Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lipovirtide injection plus nucleos(t)ide analogues in treatment‑naïve HIV-1 infected adults
CTR20233018Phase 2Active
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Nov 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lipovirtide in human immunodeficiency virus infection (HIV), sponsored by Shanxi Kangbao Biological Products. Started Nov 2023; status: active.
02
Drugs
lipovirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20233018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233018.